AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32299820
Drug: Low-dose carfilzomib
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose carfilzomib (27 mg/m2)
Trial: 32265061
Drug: DJT1116PG 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DJT1116PG 20 mg once daily for 7 days
Trial: 32265061
Drug: DJT1116PG 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DJT1116PG 50 mg once daily for 7 days
Trial: 32265061
Drug: DJT1116PG 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DJT1116PG 100 mg once daily for 7 days
Trial: 32265061
Drug: DJT1116PG (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DJT1116PG (all doses)
Trial: 33495576
Drug: rhEPO 500
RxNorm normalized name: rhTPO
DrugBank: Recombinant Human Thrombopoietin (DB16364)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhEPO 500 IU/mL plus methylprednisolone (M + E group)
Trial: 38884324
Drug: Tenecteplase (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenecteplase (0.25 mg/kg, max 25 mg)
Trial: 38884332
Drug: Alteplase (0.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alteplase (0.9 mg/kg, max 90 mg)
Trial: 33806189
Drug: Fixed prostheses
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed prostheses supported by zygomatic implants (2–4 zygomatic and 2–4 conventional implants)
Trial: 33806189
Drug: All-on-four concept
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All-on-four concept (fixed prostheses on four implants)
Trial: 36017797
Drug: Cladribine tablets
RxNorm normalized name: Cladribine
DrugBank: Cladribine (DB00242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cladribine tablets (3.5 mg/kg)
Trial: 36107485
Drug: Pre-chemotherapy NLR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-chemotherapy NLR
Trial: 36107485
Drug: NLR score
RxNorm normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NLR score = pre-chemotherapy NLR + ΔNLR
Trial: 36107485
Drug: NLR-attenuating anti-Ly6G
RxNorm normalized name: anti-CD11a
DrugBank: Efalizumab (DB00095)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: NLR-attenuating anti-Ly6G treatment with gemcitabine/paclitaxel
Trial: 33155041
Drug: Erector spinae
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erector spinae plane block (ESPB) with 30 mL 0.25% bupivacaine
Trial: 33155041
Drug: Sham block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham block with 30 mL saline
Trial: 32884045
Drug: Spinal Manipulative
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal Manipulative Therapy (SMT) at the lumbar segment measured as the stiffest
Trial: 32884045
Drug: Spinal Manipulative
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal Manipulative Therapy (SMT) at the lumbar segment measured as having the lowest pain threshold
Trial: 34463164
Drug: ospemifene 60
RxNorm normalized name: ospemifene 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ospemifene 60 mg/day for 3 months
Trial: 34463164
Drug: ospemifene 60
RxNorm normalized name: ospemifene 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ospemifene 60 mg/day for 6 months
Trial: 33212239
Drug: Patient self-monitoring
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient self-monitoring via electronic medication monitoring and smartphone application plus remote clinician feedback
Trial: 34166539
Drug: Fully guided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fully guided (FG) implant surgery
Trial: 34166539
Drug: Conventionally guided
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventionally guided (CG) implant surgery
Trial: 34090604
Drug: β‐lactam treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β‐lactam treatment for 3 days
Trial: 34562081
Drug: Peanuts (28
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peanuts (28 g/d)
Trial: 33620405
Drug: Intravenous vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous vitamin C (1.5 g), thiamine (100 mg), and hydrocortisone (50 mg) every 6 hours (n=252)
Trial: 36137125
Drug: Chemotherapeutic agents
RxNorm normalized name: Other chemotherapeutics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapeutic agents (specific agents not detailed)
Trial: 35010984
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg of bergamot phytosome® and 100 mg of artichoke leaf standardized dry extract
Trial: 32964693
Drug: Nurse-led cognitive
RxNorm normalized name: PAD,NURSING
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nurse-led cognitive behavioral group therapy for recovery of self-esteem (CBGTRS)
Trial: 34784804
Drug: Ultrasound guided
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound guided corticosteroid injection
Trial: 32471729
Drug: Abicipar 2
RxNorm normalized name: abicipar pegol
DrugBank: Abicipar Pegol (DB12258)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abicipar 2 mg every 8 weeks after 3 initial doses at baseline and weeks 4 and 8 (Q8)
Trial: 32471729
Drug: Abicipar 2
RxNorm normalized name: abicipar pegol
DrugBank: Abicipar Pegol (DB12258)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abicipar 2 mg every 12 weeks after 3 initial doses at baseline and weeks 4 and 12 (Q12)
Trial: 32471729
Drug: Ranibizumab 0.5
RxNorm normalized name: RANIBIZUMAB 0.5MG/0.05ML INJ,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab 0.5 mg every 4 weeks (Q4)
Trial: 35156069
Drug: Azithromycin 20
RxNorm normalized name: azithromycin 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 20 mg/kg biannually for a total of four treatments
Trial: 34462286
Drug: Chlorthalidone 25
RxNorm normalized name: chlorthalidone 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone 25 mg once daily for 40 weeks
Trial: 34310072
Drug: CAET combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAET combined with traditional speech and language therapy (SLT)
Trial: 32437921
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy planning according to INSEMA protocol
Trial: 32437921
Drug: Radiation dose
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiation dose in axillary level I
Trial: 32437921
Drug: Radiation dose
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiation dose in axillary levels II and III
Trial: 32437921
Drug: Association between
RxNorm normalized name: HEPATITIS ASSOCIATED ANTIBODY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Association between incidental radiation dose and obesity
Trial: 86266805
Drug: R3: rifampin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R3: rifampin plus streptomycin plus isoniazid plus pyrazinamide daily for 3 months
Trial: 86266805
Drug: R5: rifampin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R5: rifampin plus streptomycin plus isoniazid plus pyrazinamide daily for 3 months followed by streptomycin plus isoniazid plus pyrazinamide twice weekly for 2 months
Trial: 32182879
Drug: BoNT‐A injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BoNT‐A injections into each masseter muscle
Trial: 32182879
Drug: Saline injections
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline injections into each masseter muscle (placebo)
Trial: 34973039
Drug: Sertraline plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline plus enhanced medication management (SERT+EMM)
Trial: 32278278
Drug: Prolonged Exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged Exposure plus Sertraline (PE+SERT)
Trial: 32278278
Drug: Combat exposed
RxNorm normalized name: Provita Combat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combat exposed controls (CC)
Trial: 36017028
Drug: Surgical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical therapy combined with VEGF therapy (3 therapies for 1 month/time)
Trial: 36017028
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (2 therapies for 1.5 months/time)
Trial: 33450291
Drug: Drug negative
RxNorm normalized name: GLYCERIN NEGATIVE CONTROL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug negative urine
Trial: 32593046
Drug: 5-plant extract
RxNorm normalized name: century plant whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-plant extract BNO 1012 in addition to standard symptomatic therapy
Trial: 35318844
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy only
Trial: 32768592
Drug: Basiliximab induction
RxNorm normalized name: Basiliximab
DrugBank: Basiliximab (DB00074)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Basiliximab induction with low dose steroids and MMF, delayed introduction of CNI (n=42)
Trial: 32768592
Drug: Standard triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard triple immunosuppression (steroid, tacrolimus, and mycophenolate mofetil) (n=47)
Trial: 35499569
Drug: TRX518 monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRX518 monotherapy
Trial: 35499569
Drug: TRX518 in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRX518 in combination with gemcitabine (Part C)
Trial: 35499569
Drug: TRX518 in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRX518 in combination with pembrolizumab (Part D)
Trial: 35499569
Drug: TRX518 in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRX518 in combination with nivolumab (Part E)
Trial: 35499569
Drug: TRX518 monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRX518 monotherapy + anti-PD1 combination
Trial: 33822027
Drug: Heavy force
RxNorm normalized name: heavy mineral oil
DrugBank: Mineral oil (DB11057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heavy force (H, 500 g)
Trial: 33822027
Drug: Light force
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Light force (L, 300 g)
Trial: 33913086
Drug: Upadacitinib 30
RxNorm normalized name: upadacitinib 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upadacitinib 30 mg once daily
Trial: 35226949
Drug: ReWin(d) supplement
RxNorm normalized name: Benzoin resin
DrugBank: Benzoin resin (DB11222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ReWin(d) supplement
Trial: 34792542
Drug: OTTO approach
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OTTO approach (6 weeks of no treatment followed by 6 weeks of OTTO)
Trial: 32333897
Drug: Tocilizumab (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocilizumab (8 mg/kg every 4 weeks)
Trial: 32333897
Drug: Azathioprine (2‐3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azathioprine (2‐3 mg/kg per day)
Trial: 33946137
Drug: 3 mL
RxNorm normalized name: WATER,INHL 3 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mL hydro-alcoholic extract of Morus nigra leaves, three times a day
Trial: 33246911
Drug: Azithromycin (AZM),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (AZM), taken thrice-weekly for 18 months
Trial: 38191613
Drug: Atezolizumab plus
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab plus chemotherapy
Trial: 36121652
Drug: Weekly 1.7‐mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly 1.7‐mg semaglutide subcutaneous injections for 3 to 6 months
Trial: 36121652
Drug: Weekly 2.4‐mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly 2.4‐mg semaglutide subcutaneous injections for 3 to 6 months
Trial: 36121652
Drug: Weekly semaglutide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly semaglutide treatment
Trial: 33711671
Drug: Bevacizumab plus
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab plus FOLFIRI (5 mg/kg every 2 weeks)
Trial: 33711671
Drug: Cetuximab plus
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab plus FOLFIRI (400 mg/m2 then 250 mg/m2 weekly)
Trial: 35224682
Drug: Routine physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine physical therapy after BoNT‐A injection
Trial: 35730342
Drug: Topical calcipotriol/urea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical calcipotriol/urea 20% (Group D)
Trial: 616497225
Drug: Bevacizumab targeting
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab targeting therapy
Trial: 616497225
Drug: Chemotherapy regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy regimen with oxaliplatin, calcium folinate and 5-fluorouracil (Control)
Trial: 34028298
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care with bandage treatment
Trial: 35648242
Drug: Febuxostat (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Febuxostat (40 mg)
Trial: 34301661
Drug: Removal of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Removal of prescription charges for 12 months
Trial: 32237005
Drug: Behavioral economics-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral economics-based telehealth intervention (up to $50 per month for daily adherence, $2 deduction for missed doses)
Trial: 35589854
Drug: Rituximab (anti-CD20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (anti-CD20 monoclonal antibody)
Trial: 34842524
Drug: Enhanced standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced standard care plus social recovery therapy
Trial: 32755254
Drug: Enalapril 10
RxNorm normalized name: enalapril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 10 mg and folic acid 0.8 mg
Trial: 35153152
Drug: Two sterile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two sterile water injections
Trial: 35153152
Drug: Four sterile
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four sterile water injections
Trial: 33740276
Drug: Colloidal bismuth
RxNorm normalized name: Colloidal bismuth subcitrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colloidal bismuth subcitrate (CBS, 125 mg/tab)
Trial: 33740276
Drug: CBS plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBS plus high-dose proton-pump inhibitor (PPI), esomeprazole 40 mg q.i.d. for 3 days
Trial: 34887572
Drug: mRNA-1944 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA-1944 at doses of 0.1, 0.3, and 0.6 mg/kg, administered via intravenous infusion
Trial: 32677891
Drug: Early oral
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early oral refeeding (EOR)
Trial: 32677891
Drug: Usual oral
RxNorm normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual oral refeeding (UOR)
Trial: 34052414
Drug: Warming eye
RxNorm normalized name: warming eye mask
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warming eye masks generating moist heat at 40 °C for 10 min once daily for 2 weeks
Trial: 32534647
Drug: Aspirin 600
RxNorm normalized name: aspirin 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 600 mg daily
Trial: 33663581
Drug: Angiotensin-converting enzyme
RxNorm normalized name: ACE - Angiotensin-converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin-converting enzyme inhibitors, beta-blockers, calcium channel blockers
Trial: 32152335
Drug: Melinjo seed
RxNorm normalized name: Plantago Seed
DrugBank: Plantago seed (DB11097)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melinjo seed extract (MSE) 300 mg/day
Trial: 32152335
Drug: Melinjo seed
RxNorm normalized name: Plantago Seed
DrugBank: Plantago seed (DB11097)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melinjo seed extract (MSE) 500 or 1000 mg/kg/day
Trial: 36219518
Drug: Intradermal injection
RxNorm normalized name: Dryvax Intradermal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal injection of PRP (Group B, right side)
Trial: 37058173
Drug: Rituximab-chemotherapy
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab-chemotherapy
Trial: 36701005
Drug: Resistance training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resistance training (2 times weekly, 4 lower body exercises, 3 sets of 6–10 repetitions at 70–85% of 1 repetition maximum)
Trial: 35973626
Drug: Local prophylactic
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local prophylactic antibiotic therapy with vancomycin-loaded calcium sulfate beads
Trial: 35973626
Drug: Conventional IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional IV prophylactic antibiotic therapy
Trial: 33022574
Drug: Triple combination
RxNorm normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple combination of moxidectin, oxibendazole, and pyrantel pamoate
Trial: 35437881
Drug: Topical oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical oxygen therapy (TOT) and standard of care (SOC)
Trial: 33058393
Drug: Intralesional low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional low dose methylprednisolone (40 mg, once per week for 8 weeks)
Trial: 32324197
Drug: 0.016 mg
RxNorm normalized name: sulfur 0.016 MG/MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.016 mg intravitreous bevacizumab
Trial: 32324197
Drug: 0.008 mg
RxNorm normalized name: trypsin 0.008 MG/MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.008 mg intravitreous bevacizumab
Trial: 32324197
Drug: 0.004 mg
RxNorm normalized name: phenol 0.004 MG/MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.004 mg intravitreous bevacizumab
Trial: 32324197
Drug: 0.002 mg
RxNorm normalized name: niacin 0.002 MG/MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.002 mg intravitreous bevacizumab
Trial: 35944894
Drug: Peanut oral
RxNorm normalized name: Peanut Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peanut oral immunotherapy (PnOIT)
Trial: 34267006
Drug: Nonsurgical periodontal
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nonsurgical periodontal therapy (scaling and root planning) in group II (n=20)
Trial: 34942090
Drug: Vi-DT vaccine
RxNorm normalized name: Typhoid Vi polysaccharide vaccine
DrugBank: Typhoid Vi polysaccharide vaccine (DB10803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vi-DT vaccine (groups A-C)
Trial: 34942090
Drug: Vi-TT vaccine
RxNorm normalized name: Typhoid Vi polysaccharide vaccine
DrugBank: Typhoid Vi polysaccharide vaccine (DB10803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vi-TT vaccine (group D)
Trial: 38844862
Drug: Post-treatment observation
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Post-treatment observation
Trial: 32524538
Drug: Video game-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Video game-based therapy (VGBT) using Nintendo® Wii and leap motion controller (LMC) games
Trial: 35700741
Drug: Intravenous glibenclamide
RxNorm normalized name: glibenclamide
DrugBank: Glyburide (DB01016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous glibenclamide (glyburide; BIIB093) treatment
Trial: 37888913
Drug: Simvastatin (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (80 mg daily)
Trial: 35666967
Drug: Informed standardized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Informed standardized patients (expressing knowledge that antibiotics were not required)
Trial: 35666967
Drug: Uninformed standardized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uninformed standardized patients (not expressing knowledge that antibiotics were not required)
Trial: 37980801
Drug: Cognitive Processing
RxNorm normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Processing Therapy
Trial: 35187770
Drug: Originator insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Originator insulin glargine (IGlar [Lantus®])
Trial: 35667873
Drug: ONS (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ONS (oral nutritional supplements) administered twice daily for 7 days prior to surgery
Trial: 39495569
Drug: Anticoagulation treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulation treatment